How emergency blood-cell production may drive AML progression
Project 1: Role of emergency myelopoiesis as a driver of clonal evolution in AML
This work looks at whether emergency-style production of certain blood cells helps leukemia cells grow in people with or at risk for acute myeloid leukemia.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11181645 on NIH RePORTER |
What this research studies
This project studies how emergency myelopoiesis — the bone marrow’s rapid response to stress or inflammation — might be hijacked during aging or disease to promote leukemia. Researchers will examine how stem and progenitor blood cells change their signaling, gene activity, and epigenetic regulation during these emergency responses. The team will explore links between inflammation, age-related clonal hematopoiesis (such as DNMT3A mutations), and evolution toward AML. Work will be carried out through laboratory and translational studies at Columbia to trace these pathways and their role in disease development.
Who could benefit from this research
Good fit: People with acute myeloid leukemia, individuals with age-related clonal hematopoiesis (for example DNMT3A mutations), or those judged at higher risk for AML would be the most relevant candidates.
Not a fit: People without myeloid blood disorders or those with conditions unrelated to AML (for example most solid-tumor patients) are unlikely to directly benefit from this project.
Why it matters
Potential benefit: If successful, this could identify new targets to prevent or slow AML by blocking the emergency myelopoiesis processes that allow mutant cells to expand.
How similar studies have performed: Prior research has suggested links between emergency myelopoiesis, inflammation, and clonal blood disorders, but translating these findings into human treatments is still largely unproven.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Passegue, Emmanuelle — Columbia University Health Sciences
- Study coordinator: Passegue, Emmanuelle
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.